These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 2960447

  • 1. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
    Sano H, Kosugi A, Sano S, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
    [Abstract] [Full Text] [Related]

  • 2. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
    Shima J, Yoshioka T, Nakajima H, Fujiwara H, Hamaoka T.
    Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
    [Abstract] [Full Text] [Related]

  • 3. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
    Hamaoka T, Takai Y, Kosugi A, Mizushima Y, Shima J, Kusama T, Fujiwara H.
    Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
    [Abstract] [Full Text] [Related]

  • 4. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H, Aoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T.
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [Abstract] [Full Text] [Related]

  • 5. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
    Kosugi A, Shima J, Sano H, Ogata M, Kusama T, Fujiwara H, Hamaoka T.
    Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
    [Abstract] [Full Text] [Related]

  • 6. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.
    Sato S, Fujiwara H, Kosugi A, Hamaoka T.
    Cancer Immunol Immunother; 1987 Dec; 24(2):121-6. PubMed ID: 3493845
    [Abstract] [Full Text] [Related]

  • 7. Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide derivative-coupled tumor cells.
    Fujiwara H, Shima J, Sano H, Kosugi A, Nakajima H, Hamaoka T.
    Prog Clin Biol Res; 1987 Dec; 244():335-44. PubMed ID: 2958872
    [Abstract] [Full Text] [Related]

  • 8. [The augmentation of tumor-specific immunity by T-T cell interaction].
    Fujiwara H, Takai Y, Fukuzawa M, Yoshioka T, Izumi Y, Mizushima Y, Qian J, Ogata M, Kosugi A, Nakajima H.
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):734-40. PubMed ID: 3157349
    [Abstract] [Full Text] [Related]

  • 9. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T.
    J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
    [Abstract] [Full Text] [Related]

  • 10. [Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity].
    Hamaoka T.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):886-96. PubMed ID: 2786376
    [Abstract] [Full Text] [Related]

  • 11. Effect of helper T cells on prevention of tolerance induction in effector T cells responsible for syngeneic tumor immunity.
    Fujiwara H, Kinouchi T, Tsuchida T, Aoki H, Hamaoka T.
    Gan; 1982 Oct; 73(5):766-72. PubMed ID: 6219908
    [Abstract] [Full Text] [Related]

  • 12. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
    Yoo YC, Saiki I, Sato K, Azuma I.
    Vaccine; 1992 Oct; 10(11):792-7. PubMed ID: 1441733
    [Abstract] [Full Text] [Related]

  • 13. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
    Shimizu Y, Hasumi K, Masubuchi K, Okudaira Y.
    Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
    [Abstract] [Full Text] [Related]

  • 14. Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.
    Hamaoka T, Fujiwara H, Teshima K, Aoki H, Yamamoto H, Kitagawa M.
    J Exp Med; 1979 Jan 01; 149(1):185-99. PubMed ID: 310858
    [Abstract] [Full Text] [Related]

  • 15. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
    Suda T, Fujiwara H, Mizushima Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1986 Dec 01; 77(6):1267-72. PubMed ID: 2948049
    [Abstract] [Full Text] [Related]

  • 16. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
    Takatsu K, Hamaoka T, Tominaga A, Kanamasa Y.
    J Immunol; 1980 Dec 01; 125(6):2367-73. PubMed ID: 6776192
    [Abstract] [Full Text] [Related]

  • 17. Effects of hapten epitope structure and hapten-self conjugation pattern on T cell specificity and Ir gene control in hapten-self cytotoxic and helper T cell responses.
    Takai Y, Mizuochi T, Fujiwara H, Hamaoka T.
    J Immunol; 1984 Jan 01; 132(1):57-62. PubMed ID: 6197460
    [Abstract] [Full Text] [Related]

  • 18. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
    Yamamoto K, Kato K, Kakinuma M, Okuyama H, Azuma I.
    Immunology; 1982 Jun 01; 46(2):473-9. PubMed ID: 7044961
    [Abstract] [Full Text] [Related]

  • 19. Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses.
    Mizushima Y, Fujiwara H, Takai Y, Shearer GM, Hamaoka T.
    J Natl Cancer Inst; 1985 Jun 01; 74(6):1269-73. PubMed ID: 3158772
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.
    Bubeník J, Jezek J, Zaoral M, Hofmann J, Gruntenko YV, Osipov JG, Zolotareva AG, Vakhrusheva TE, Budker VG.
    Cancer Immunol Immunother; 1984 Jun 01; 18(2):123-5. PubMed ID: 6568871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.